Drugs / SSS40
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06022536 | Aug → Oct 2023 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07008703 | Mar 2024 → Dec 2025 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS40 | “This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in...” NCT07008703 ↗ |
| Route | Subcutaneous | “1mg SSS40 was injected subcutaneously on day1.” NCT06022536 ↗ |